Recent Advances in Biologic Treatments

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across biologic treatments. In particular, proteomic and microbiome therapies are profiled. The corresponding clinical trials scenario for individualized cancer therapies is depicted, along with industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellu

Table of Contents

Recent Advances in Biologic TreatmentsRecent Developments in Proteomic and Microbiome TherapiesLiquid Biopsy Platform for Monitoring Cancer Immunotherapy ResponseGenomically Recoding Bacteria to Produce Therapeutic ProteinsCaplacizumab Meets Primary Endpoint in Phase III StudySeres Reports Positive Topline Results for SER-287 in Phase I StudyClinical Trial Analysis and Industry InteractionsClinical Trial Analysis for Individualized Cancer TherapiesSummary of Key Contacts

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.